About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed
LOGIN
My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Drug Repurposing, Rescue, and Repositioning

Editor-in-Chief: Aris Persidis

Editor: Hermann Mucke

ISSN: 2332-0257 • Published Quarterly • Online ISSN: 2332-0265

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Drug Repurposing, Rescue, and Repositioning is the international forum for original research into the field of drug new use and innovation. Through peer-reviewed original research, case studies, technology reviews, and other original content, Drug Repurposing, Rescue, and Repositioning showcases the progress in one of the most exciting and impactful areas of biomedical research today.

    Drug Repurposing, Rescue, and Repositioning coverage includes:

    • Interpreting assay outputs to enable alternate drug target identification
    • Pathway analysis and bioinformatics to identify and exploit drug promiscuity
    • In silico technologies to identify alternate drug targets
    • "Big Data" mining and side effect pattern analysis in clinical and healthcare repositories
    • Knowledge extraction from literature and patents in support of target space extension
    • Drug repurposing towards neglected and orphan diseases
    • Drug reformulation and alternative routes of administration
    • Cost containment and risk mitigation in drug or candidate re-development
    • Obtaining and defending intellectual property for new uses of known compounds
    • Designing and optimizing the approval process for new indications
    • The social and financial impact of accelerated development drug repositioning programs

    SUBMISSION OF MANUSCRIPTS
    Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication, elsewhere except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the manuscript title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal. By submitting a manuscript to the Journal, the author(s) agree(s) to these conditions.  Certain exceptions from this rule apply (ex: some government employees, or work presented on behalf of governmental agencies).


    NOTE:

    All submitted manuscripts will be processed through plagiarism detection software. Plagiarized manuscripts will be rejected immediately.

    Manuscripts should be submitted to http://mc.manuscriptcentral.com/drugrepurposing


    Please read all the instructions to authors before submitting.


    USE OF ENGLISH LANGUAGE


    All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in Drug Repurposing, Rescue, and Repositioning.  For authors whose native language is not English, we suggest using a service that can aid in the translation and rewriting of material into correct and proper English usage.  The Publisher offers this service with a subsidy from the author prior to official submission (contact AuthorServices@liebertpub.com).  It is important to note that employing the use of the Publisher’s service does not guarantee acceptance of any paper.  All submissions are subject to peer review.

     

    PEER REVIEW

    All submissions to the Journal are subject to peer review.  Authors are encouraged, but not required, to supply the names and email addresses of three to four individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors would prefer not be selected as a reviewer. However, the review selection is ultimately at the discretion of the Editor.

    AUTHORSHIP

    All authors, including the co-authors, should be responsible for a significant part of the manuscript. All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content. Any author whose name appears on a paper assumes responsibility and accountability for the results.

    It is incumbent upon the submitting author to ensure the accuracy and inclusion of all contributing authors’ names and affiliations upon original submission of the paper. Once a paper is accepted for publication, changes in authorship are NOT permitted. Changes in authorship after publication are strictly prohibited.


    Working Groups or Committees as Authors
    Working Groups and/or Committees should NOT be listed as an author.  Instead, the name of the Working Group and/or Committee and all of the participants, should be listed in the Acknowledgments section of the manuscript.

    Corresponding Authorship

    It is the Journal’s policy that only ONE corresponding author is listed on a paper. This designation should be determined at the time of submission. Additions to corresponding authors are not permitted after acceptance or in page proofs.


    PREPARATION OF MANUSCRIPTS

    Word Limits


    Article Type

    Maximum Word Limit*

    Abstract Word Limit

    Maximum #

    of References

    Maximum # of Figures

    Maximum # of Tables

    Original

    5,000-6,000

    250

    100

    12

    6

    Invited Review

    8,000-12,000

    250

    250

    12

    6

    Methods

    5,000-6,000

    250

    100

    6

    6

    Case Study

    2,000-3,000

    250

    20

    6

    2

    Commentary

    1,000

    150

    (Inclusion of abstract is optional)

    4

    1

    1

    Letters to the Editor

    1,000

    N/A

    4

    1

    1

    *These limits relate to the text of the manuscript; word limits do NOT include the abstract, figure and/or table legends, acknowledgments, disclosures, or references
       

    • All text submissions must be provided in Word.  Do not submit PDFs of the manuscript or any text files.  Submissions containing PDFs of text files will be returned without review.

    •  All manuscript pages should be double spaced.

    •  Include a title page that contains:
    — The full title of the manuscript
    — All contributing authors’ full names
    — All contributing author’s complete affiliations
    — A short title of no more than 50 characters, including spaces
    — At least 4 (four) keywords [maximum of 8 (eight)]
    • Supply an abstract as the second page of text.

    After the abstract, the text should be constructed as follows:

     

    • Text: Organize the text as follows: Introduction; Materials and Methods; Results; Discussion; Conclusions; Acknowledgments; Disclosure; and References. At the first usage of a term, spell out the term and then provide the abbreviation or acronym in parentheses. Thereafter, use the abbreviation/acronym alone.

    • Acknowledgments: The author should acknowledge only those people and institutions that have made significant contributions to the study.

    • Disclosure Statement: Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being
      reviewed and will not influence the editorial decision. If no conflicts exist, the authors must state “No competing financial interests exist.”

    • References: The references should be cited in the text using the American Medical Association’s (AMA) reference style.
      • Items are listed numerically in the order they are cited in the text
      • Include up to six (6) authors
      • For references containing more than six authors, list the first three (3), followed by et al
      • If no author is listed, start with the article/book title
      • Journal titles in the reference listed should be abbreviated according to Medline
    • For accepted papers not yet published, cite the journal and add "in press." If references to personal communications or unpublished data are used, cite them parenthetically in the text, not in the references. Sources for personal communications must provide written approval at the time of submission. Authors are responsible for the accuracy of references.

     

    Sample references:

    Journal example:  Timmerman L, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.  Cancer Cell. 2013;24;450–465.

    Book example :  Barratt MJ, Frail D.  Drug Repositioning:   Bringing New Life to Shelved Assets and Existing Drugs.  Hoboken, NJ: Wiley & Sons; 2012.


    Chapter in a Book example:  Mochizuki A, Aoyama A.   A case study in drug repositioning:  Sosei.  In:  Barratt MJ, Frail D., eds.  Drug Repositioning:   Bringing New Life to Shelved Assets and Existing Drugs.  Hoboken, NJ: Wiley & Sons; 2012:445–456.

    Abstract:  Doudican NA. et al. In vitro validation of rationally designed therapeutic based on drug repositioning and combinations . Abstract number 2104 from the American Association for Cancer Research Annual Meeting; Washington DC,  April 6–10, 2013.

    Website references:  Please follow this structure for website references,  including capitalization and punctuation:

    List author/organization name (if available).  Article title.  Provide website address.  Include last accessed date.

    Conference Proceedings:  Please follow this structure for Conference Proceeding references, including capitalization and punctuation:

    List all Authors’ (or) Editors’ names (last name first, followed by first and middle initials).  Conference title. Date of conference. Location of conference. City of publisher: Publisher; Year of publication. Complete number of pages in proceedings book.

    •    Correspondence address: After the references, provide the name, address, and e-mail of the person to whom all correspondence should be directed. This information will be included at the end of the references in the final published version of the article.

    Unpublished Material
    When a reference is unpublished data, a manuscript in preparation, or a manuscript submitted but not in press, it should be included in parentheses in the body of the text, and not cited in the reference list. Personal communications should also be listed parenthetically in text, and should contain the first initial and last name of the contact, as well as the month and year of the communication. Published manuscripts, and those that have been accepted and are pending publication, should be cited in the reference list.

    TABLES

    Submit table(s), each with its own title, as a separate file from the text of the manuscript. Use Arabic numerals to number tables. Table legends and/or footnotes should be double-spaced.

    FIGURES

    Prepare a separate list of figure legends, double-spaced, at the end of the manuscript file.


    Please follow these guidelines for submitting figures.

    • Do NOT embed art files into a Word or PDF document.
    • Line illustrations should be submitted at a minimum of 900 dpi.
    • Halftones and color should be submitted at a minimum of 300 dpi.
    • Black and White art must be submitted as grayscale—not RGB.
    • Save as either TIFF or EPS files.
    • Color art must be saved as CYMK—not RGB.
    • PowerPoint and Excel files cannot be accepted.
    • Name figure files using only alphanumeric characters.  Do not use symbols, dots, or dashes.
    • File names should be formatted with first author’s last name and the figure number. (Ex:  SmithFig1).

     

    COLOR FIGURES

    The cost of printing figures in color must be subsidized by the author(s). Cost estimates are available from the Publisher upon request.

     

    COPYRIGHT

    Upon acceptance of any manuscript, all authors will receive a follow-up email with instructions on how to complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications.

    The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.

           If a co-author does not receive the proper email, the pending copyright form may be completed by logging on to the Manuscript Central system using the author’s credentials.  Click on Author Center and complete the forms located under “Manuscripts I Have Coauthored,” or “Manuscripts with Decisions” if you are listed as the corresponding author on the paper.

    Failure by all authors to submit this form will result in a delay in publication.

    RELEASE INFORMATION

    If applicable, it is incumbent upon the author(s) to obtain release statements of permission to reproduce any identifiable images of individuals. The submitting author should provide written confirmation of this critical information. Acceptable forms of consent statements are emails or letters. The Journal does not provide a generic patient release form.

    The written consent must contain specific information about the individual's name, age, and if pertinent, conservatorship -- as well as stated permission -- granting the Journal the rights to publish the photograph within its pages (which includes the name of the Journal and article title).

    The Publisher is not responsible for the publication of any identifiable information in a manuscript or any of its accompanying material.

    PERMISSIONS

    Figures, tables, and text taken from other sources must be accompanied by a written statement from both author and publisher, granting permission for reproduction Include written permission from authors to cite unpublished data or papers still in press.

    PAGE PROOFS
    Page proofs will be sent to the (one) corresponding author as designated when the manuscript was uploaded to Manuscript Central. It is the corresponding author’s responsibility to share the page proofs with co-authors and to coordinate all authors’ corrections into one proof. The Publisher will not accept corrections from multiple authors.

    Once a paper is accepted for publication, changes in authorship in the page proof stage are NOT permitted under any circumstance.

    REPRINTS

    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

    PUBLISHER

    Drug Repurposing, Rescue, and Repositioning  is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801. Tel: 914-740-2100; Fax: 914-740-2108; Email: info@liebertpub.com; Website: www.liebertpub.com

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy


    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

     

    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 

     

     

     

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    ASSAY and Drug Development Technologies

    ASSAY and Drug Development Technologies

    This authoritative, rapidly peer-reviewed journal features original articles, application-oriented technology reviews, and reports in methodology and technology application.

    Genetic Engineering & Biotechnology News

    Genetic Engineering & Biotechnology News

    The mostly widely-read publication covering tools, techniques, and technologies in the biotechnology industry.

    Big Data

    Big Data

    This highly innovative, peer-reviewed journal, provides a unique forum for world-class research exploring the challenges and opportunities surrounding the growing field data science.

    Biotechnology Law Report

    Biotechnology Law Report

    The leading journal devoted to the evolving body of law and government regulation concerning biotechnology, particularly in the industries in which new products from these technologies are developing the most rapidly.

Browse All Publications »

New Video Message from Editor-in-Chief Aris Persidis and Editor Hermann Mucke